Global In-Vitro Diagnostics Market Overview

The global In-vitro diagnosis market was valued at USD 63.5 billion in 2018 and t is expected to grow at a healthy CAGR of 4.0% during 2019-2026.

Market Scenario

In-vitro diagnosis is the technique used to identification of disease, infection and other genetic conditions. A variety of techniques are developed for the monitoring process. The global in-vitro diagnosis market is majorly driven by increasing prevalence of chronic & infectious diseases, technological advances and rising geriatric population. During last decade, there is a significant increase in the number of patients suffering from diabetes. According to the World Health Organization (WHO), in 2014, 422 million people across the globe are suffering from diabetes. This has led to increase in the number of public and private diagnostic centers across the globe which has boosted the growth of the market. Moreover, increasing healthcare expenditure and gove
ment initiatives have fueled the growth of the market.

However, stringent gove
ment regulations for IVD products and reagents and poor reimbursement policies may slow the growth of the market during the forecasted period. Emerging economies are increasing the investments in research sector with rapidly increasing demand for the better diagnostic test have served as a opportunity for the development of the market. 

The global In-vitro diagnostics market is expected to grow at a steady CAGR of 4.9% during 2018-2026.

Segmentation

The global in-vitro diagnostics market is segmented based on products, techniques, applications and end users.

Based on products, the market is segmented into reagents, instruments, software & services.

Based on techniques, the market is segmented into immunodiagnostics, blood glucose monitoring, point-of-care, molecular diagnostics, tissue diagnostics, and others.

Based on application, the market is segmented into diabetic care, infectious diseases, cancer, nephrological diseases, immune system disorders, gastrointestinal diseases.

Based on end users, the market is segmented into hospitals & clinics, research laboratories, and others.

Regional Analysis

The global in-vitro market is dominated by America owing well developed technology, high healthcare spending and huge patient population suffering from diabetes and cancer. Additionally, presences of geriatric population and gove
ment support have fuelled the market growth in America. 

Europe accounts for the second leading market which is followed by Asia Pacific. Strong gove
ment support and favorable research policies have driven the growth of Europe market. Germany dominates the Europe IVD market. In 2017, the German IVD-Market witnessed slight decline in the sales. However, the market development differed strongly between the various segments. Laboratory diagnostics continue to increase similarly to the previous years. A major decline can be found for the rapid market where the negative market trend of 2016 continues. After 2017, German market has been witnessing significant growth due to several factors. Major factors include, restrictive legal framework that forces medical doctors to prescribe generic, low-priced test strips to not overstep their respective budget remains in place. In addition to this, the shift to new sensor-based technologies for the measurement of glucose continues in Germany. Until the flash glucose monitoring / continuous glucose monitoring is not included in the GIVD classification and due to the current market situation with only a very few numbers of competitors, the positive development of these technologies cannot be reproduced exactly. Still, regulatory environment in Germany remains strict. The floating quota percentage for laboratory service fees remains in place and unchanged in 2017. Consequently, price pressure does stay strong in the German IVD-Market. However, despite this various market segments continue to thrive.

Asia Pacific is the fastest growing market due to huge untapped opportunity for the development of the market. 

On the other hand, the Middle East & Africa holds the least share in the market due to presence of poor economies in Africa region.

Key Players

The key players in the market are: F. Hoffmann-La Roche Ltd (Switzerland), Danaher (U.S.), Abbott Laboratories (U.S.), Siemens Healthcare GmbH (Germany), QIAGEN (Germany), Johnson & Johnson Services, Inc. (U.S.), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Alere (U.S.), and Ortho Clinical Diagnostics (U.S.)

Segmentation

Global In-Vitro Diagnostics Market, By Products

Reagents

Instruments

Software and Services

Global In-Vitro Diagnostics Market, By Techniques

Immunodiagnostics

Enzyme-Linked Immunosorbent Assay (ELISA)    

Chemiluminescence Immunoassays (CLIAS)

Fluorescence Immunoassays (FIAS)

Colorimetric Immunoassays (CIS)

Others

Enzyme-Linked Immunospot Assays (ELISPOT)    

Radioimmunoassay

Weste
Blot    

Others    

Blood Glucose Monitoring

Point of Care

Molecular Diagnostics

Polymerase Chain Reaction (PCR)    

Hybridization

DNA Diagnostics

Microarrays

Others

Tissue Diagnostics

Immunohistochemistry (IHC) test

Fluorescent in situ hybridization (FISH)

Silver in situ hybridization (SISH)

Others

Other

By Application

Diabetic Care

Infectious Diseases

Cancer

Nephrological Diseases

Immune System Disorders

Gastrointestinal Diseases

Other

Global In-Vitro Diagnostics Market, By End Users

Hospitals & Clinics

Research Laboratories

Others

Global In-Vitro Diagnostics Market players

F. Hoffmann-La Roche Ltd 

Danaher

Abbott Laboratories

Siemens Healthcare GmbH 

QIAGEN 

Johnson & Johnson Services, Inc.

Thermo Fisher Scientific

Bio-Rad Laboratories, Inc.

Dickinson and Company

Alere

Ortho Clinical Diagnostics (U.S.)